Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie Device Maker Analytica Pushing Out E-Health Incontinence System

This article was originally published in PharmAsia News

Executive Summary

Analytica’s smart phone application features a feedback loop to help women with incontinence and allows physicians to gauge progress for added incentive and compliance value.

You may also be interested in...



Wearable Fitness Technology Could Foretell The Future Of Remote Patient Monitoring

Wearable wireless monitoring devices geared toward the fitness market are beginning to attract the attention of the health care industry, which recognizes the technology’s potential to provide an ideal patient monitoring tool. As more of this technology makes its way into the clinical setting, this trend is poised to change the traditional view of what is and is not a medical device.

Prima Shifts Focus To LAG-3 After Immutep Deal

The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.

Phylogica Surges On Early CPP Cancer Results

Phylogica is continuing its strong financial year, with the company’s shares surging after it announced that a pilot study for its cell-penetrating peptides (CPPs) showed these were able to kill drug-resistant breast cancer cells in vivo, when linked with the cancer drug Omomyc.

Topics

UsernamePublicRestriction

Register

SC086293

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel